多聚唾液酸在肿瘤治疗中的研究进展

doi:10.3969/j.issn.1004-616x.2025.02.014

癌变·畸变·突变 ›› 2025, Vol. 37 ›› Issue (2): 170-174.doi: 10.3969/j.issn.1004-616x.2025.02.014

多聚唾液酸在肿瘤治疗中的研究进展

刘佳文^1,2, 乐乐^1,2, 梁徐睿^1,2, 张志豪³, 张涛^1,2

1. 南京医科大学药学院核药学系, 江苏南京 211166;
2. 南京医科大学核医药临床转化中心, 江苏南京 210029;
3. 中国科学院生物物理研究所生物大分子全国重点实验室, 北京 100101

收稿日期:2024-08-30 修回日期:2025-03-05 出版日期:2025-03-30 发布日期:2025-04-11
通讯作者: 张涛
作者简介:刘佳文，E-mail:3215948907@qq.com。
基金资助:
江苏省高等学校大学生创新创业训练计划项目(202310312075Y，202410312080Y)

^1,2

Received:2024-08-30 Revised:2025-03-05 Online:2025-03-30 Published:2025-04-11

摘要/Abstract

摘要： 多聚唾液酸(PSA)是一类由α-2,8糖苷键连接的线性均一唾液酸多聚物，具有多种生物学活性。PSA不仅在神经系统发育和维持中发挥关键作用，还参与调控肿瘤转移(如乳腺癌、黑色素瘤等)和炎症反应等病理过程。尽管PSA在肿瘤发展中的作用机制已引起广泛关注，但其在抗肿瘤药物研发中的应用仍处于初步探索阶段，相关研究分散且缺乏系统性总结。此外，基于PSA的药物递送系统因其独特的生物相容性和靶向性，展现出巨大的潜力，但相关进展尚未得到全面梳理。因此，本文旨在系统综述PSA在抗肿瘤药物研发中的最新进展，并探讨基于PSA的药物递送系统的设计策略和应用前景。

关键词: 多聚唾液酸, 肿瘤, 神经疾病, 精神疾病, 炎症, 药物递送

中图分类号:

R730.58

刘佳文, 乐乐, 梁徐睿, 张志豪, 张涛. 多聚唾液酸在肿瘤治疗中的研究进展[J]. 癌变·畸变·突变, 2025, 37(2): 170-174.

参考文献

[1] MINDLER K, OSTERTAG E, STEHLE T. The polyfunctional polysialic acid:a structural view[J]. Carbohydr Res, 2021, 507:108376.
[2] 吴剑荣, 彭星桥, 詹晓北. 聚唾液酸, 一种非GAGs、非免疫原性生物材料的应用研究进展[J]. 中国生物工程杂志, 2017, 37(12):96-102.
[3] COLLEY K J, KITAJIMA K, SATO C. Polysialic acid:biosynthesis, novel functions and applications[J]. Crit Rev Biochem Mol Biol, 2014, 49(6):498-532.
[4] 杨颜睿, 黄秋映, 杜宇航, 等. 基于多聚唾液酸的药物递送系统研究进展[J]. 中国药师, 2023, 26(12):491-498.
[5] 王梦花, 林小仙, 琚萌萌, 等. 唾液酸的制备和生物活性研究进展[J]. 药学研究, 2022, 41(9):600-604.
[6] 王欣, 关锋. 多聚唾液酸(PSA)及其修饰的神经粘附分子(PSA-NCAM)对肿瘤及细胞信号通路的影响[J]. 遗传, 2014, 36(8):739-746.
[7] JARAHIAN M, MAROFI F, MAASHI M S, et al. Re-expression of poly/oligo-sialylated adhesion molecules on the surface of tumor cells disrupts their interaction with immune-effector cells and contributes to pathophysiological immune escape[J]. Cancers, 2021, 13(20):5203.
[8] 周文波, 周长福. 神经细胞粘连分子和多聚唾液酸在神经发育和再生中的作用[J]. 生理科学进展, 1996, 2:118-122.
[9] SENKOV O, TIKHOBRAZOVA O, DITYATEV A. PSA-NCAM:synaptic functions mediated by its interactions with proteoglycans and glutamate receptors[J]. Int J Biochem Cell Biol, 2012, 44(4):591-595.
[10] WI-FELD J, ABOU ASSALE T, CUEVAS-RIOS G, et al. Therapeutic potential to target sialylation and SIGLECs in neurodegenerative and psychiatric diseases[J]. Front Neurol, 2024, 15:1330874.
[11] THIESLER H, BEIMDIEK J, HILDEBRANDT H. Polysialic acid and Siglec-E orchestrate negative feedback regulation of microglia activation[J]. Cell Mol Life Sci, 2021, 78(4):1637-1653.
[12] LIAO H, WINKLER J, WI-FELD J, et al. Low molecular weight polysialic acid prevents lipopolysaccharide-induced inflammatory dopaminergic neurodegeneration in humanized SIGLEC11 transgenic mice[J]. Glia, 2021, 69(12):2845-2862.
[13] ULM C, SAFFARZADEH M, MAHAVADI P, et al. Soluble polysialylated NCAM:a novel player of the innate immune system in the lung[J]. Cell Mol Life Sci, 2013, 70(19):3695-3708.
[14] 魏江洲, 周文丽, 郭婷婷, 等. 多聚唾液酸与多聚唾液酸转移酶[J]. 生命的化学, 2005, 25(6):473-475.
[15] RILLAHAN C D, ANTONOPOULOS A, LEFORT C T, et al. Global metabolic inhibitors of sialyl- and fucosyltransferases remodel the glycome[J]. Nat Chem Biol, 2012, 8(7):661-668.
[16] MOONS S J, ROSSING E, JANSSEN M A C H, et al. Structure-activity relationship of metabolic sialic acid inhibitors and labeling reagents[J]. ACS Chem Biol, 2022, 17(3):590-597.
[17] HEISE T, PIJNENBORG J F A, BÜLL C, et al. Potent metabolic sialylation inhibitors based on C-5-modified fluorinated sialic acids[J]. J Med Chem, 2019, 62(2):1014-1021.
[18] HUNTER C, GAO Z Z, CHEN H M, et al. Attenuation of polysialic acid biosynthesis in cells by the small molecule inhibitor 8-keto-sialic acid[J]. ACS Chem Biol, 2023, 18(1):41-48.
[19] LIAO S M, LIU X H, PENG L X, et al. Molecular mechanism of inhibition of polysialyltransferase domain (PSTD) by heparin[J]. Curr Top Med Chem, 2021, 21(13):1113-1120.
[20] LIAO S M, LU B, LIU X H, et al. Molecular interactions of the polysialytransferase Doma in (PSTD) in ST8Sia IV with CMP-sialic acid and polysialic acid required for polysialylation of the neural cell adhesion molecule proteins:an NMR study[J]. Int J Mol Sci, 2020, 21(5):1590.
[21] GIFFORD J L, HUNTER H N, VOGEL H J. Lactoferricin:a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties[J]. Cell Mol Life Sci, 2005, 62(22):2588-2598.
[22] LU B, LIAO S M, LIANG S J, et al. The bifunctional effects of lactoferrin (LFcinB11) in inhibiting neural cell adhesive molecule (NCAM) polysialylation and the release of neutrophil extracellular traps (NETs)[J]. Int J Mol Sci, 2024, 25(9):4641.
[23] ECK R J, ELLING T, SUTTON A J, et al. Anticoagulants for thrombosis prophylaxis in acutely ill patients admitted to hospital:systematic review and network meta-analysis[J]. BMJ, 2022, 378:e070022.
[24] TANG N, LI H H, ZHANG L H, et al. A macromolecular drug for cancer therapy via extracellular calcification[J]. Angew Chem Int Ed, 2021, 60(12):6509-6517.
[25] COX E C, THORNLOW D N, JONES M A, et al. Antibody-mediated endocytosis of polysialic acid enables intracellular delivery and cytotoxicity of a glycan-directed antibody-drug conjugate[J]. Cancer Res, 2019, 79(8):1810-1821.
[26] STEIRER L M, MOE G R. An antibody to de-N-acetyl sialic acid containing-polysialic acid identifies an intracellular antigen and induces apoptosis in human cancer cell lines[J]. PLoS One, 2011, 6(11):e27249.
[27] LEHTI T A, PAJUNEN M I, JOKILAMMI A, et al. Design of a cytotoxic neuroblastoma-targeting agent using an enzyme acting on polysialic acid fused to a toxin[J]. Mol Cancer Ther, 2021, 20(10):1996-2007.
[28] MARTIN N T, WREDE C, NIEMANN J, et al. Targeting polysialic acid-abundant cancers using oncolytic adenoviruses with fibers fused to active bacteriophage borne endosialidase[J]. Biomaterials, 2018, 158:86-94.
[29] ZHANG Q X, LI S S, HE L, et al. A brief review of polysialic acid-based drug delivery systems[J]. Int J Biol Macromol, 2023, 230:123151.
[30] RODE B, ENDRES C, RAN C, et al. Large-scale production and homogenous purification of long chain polysialic acids from E. coli K1[J]. J Biotechnol, 2008, 135(2):202-209.
[31] LI X, GUAN S, LI H N, et al. Polysialic acid-functionalized liposomes for efficient honokiol delivery to inhibit breast cancer growth and metastasis[J]. Drug Deliv, 2023, 30(1):2181746.
[32] SHIM M K, NA J, CHO I K, et al. Targeting of claudin-4 by Clostridium perfringens enterotoxin-conjugated polysialic acid nanoparticles for pancreatic cancer therapy[J]. J Control Release, 2021, 331:434-442.
[33] XU J, LI Y A, CHEN Y, et al. Preparation and characterization of a novel polysialic acid/gelatin composite hydrogels cross-linked by tannic acid to improve wound healing after cesarean section dressing[J]. J Biomater Sci Polym Ed, 2021, 32(15):1927-1943.
[34] SUN J, TIAN Q J, LIU M, et al. Evaluation of the antitumor effect and immune response of micelles modified with a polysialic acid-D-α-tocopheryl polyethylene glycol 1000 succinate conjugate[J]. AAPS PharmSciTech, 2021, 22(7):223.

多聚唾液酸在肿瘤治疗中的研究进展

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	高天, 王振, 曹猛, 李飞, 师敏婕, 刘江正, 刘瑞, 吴昊, 海春旭. 咖啡酸苯乙酯对光气诱导大鼠急性肺损伤的保护作用及其机制[J]. 癌变·畸变·突变, 2025, 37(2): 113-120.
[2]	蔡静明, 沃晓辉, 王勇, 朴美月, 康志强. 2019年呼伦贝尔市恶性肿瘤流行情况分析[J]. 癌变·畸变·突变, 2025, 37(2): 134-139.
[3]	李宏伟, 刘江正, 孔德钦, 孙明继. 四氧化二氮诱导急性肺损伤的机制及救治研究进展[J]. 癌变·畸变·突变, 2025, 37(2): 166-169,174.
[4]	曹猛, 王振, 高天, 于卫华, 刘江正, 孔德钦, 吴昊, 龙子, 王钊, 刘瑞, 海春旭. 咖啡酸苯乙酯对硫芥诱导小鼠急性肺损伤的保护作用研究[J]. 癌变·畸变·突变, 2025, 37(1): 8-15.
[5]	郭秀娟, 贾聿明, 颜晰, 赵红峥, 郭奕阳, 张金艳. 半胱氨酸蛋白酶抑制剂4在胰腺癌临床诊断及预后评估中的价值[J]. 癌变·畸变·突变, 2024, 36(6): 463-469.
[6]	李子烜, 黄吉, 孙震晓. 顺铂诱导多倍体肿瘤巨细胞模型的构建[J]. 癌变·畸变·突变, 2024, 36(6): 483-490.
[7]	何改花, 范珊红, 李文丽. α1-抗胰蛋白酶的功能及其与肺部疾病关系的研究进展[J]. 癌变·畸变·突变, 2024, 36(6): 502-505.
[8]	杨莉, 苟巧. E2F转录因子4在肿瘤中的研究进展[J]. 癌变·畸变·突变, 2024, 36(6): 506-509.
[9]	张鑫桐, 顾勐, 王子宇, 韦攀健, 王敬慧, 谭金晶. 血糖对EGFR突变肺腺癌患者靶向治疗耐药的影响及其机制[J]. 癌变·畸变·突变, 2024, 36(5): 365-372,383.
[10]	郭采妮, 刘璟, 张玉龙, 丁黎, 付步芳. 硅凝胶乳房植入物相关疾病的研究进展[J]. 癌变·畸变·突变, 2024, 36(5): 412-416.
[11]	寿建忠. 解密前列腺癌——从容和科学面对[J]. 癌变·畸变·突变, 2024, 36(4): 253-255,260.
[12]	李佳威, 郭晓洁, 师敏婕, 李文丽, 刘江正. 雾化吸入NaClO致小鼠肺损伤模型的构建及机制研究[J]. 癌变·畸变·突变, 2024, 36(4): 281-287,297.
[13]	李子烜, 孙震晓. 基于多倍体肿瘤巨细胞的抗肿瘤研究进展[J]. 癌变·畸变·突变, 2024, 36(4): 325-327,333.
[14]	张开泰. 衰老与恶性肿瘤——被忽视的免疫衰老[J]. 癌变·畸变·突变, 2024, 36(3): 169-171.
[15]	孙小宁, 苏德奇, 杨浩峰, 田亚绒, 刘慧, 黄小溪. 臭氧急性暴露对大鼠肺组织损伤的影响[J]. 癌变·畸变·突变, 2024, 36(3): 219-223.